Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel R Altmann

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Neurology|December 18, 2015
White and gray matter damage in primary progressive MS: The chicken or the egg?Benedetta Bodini, Declan Chard, Daniel R Altmann, et al.
Neurology|December 26, 2014
Cervical cord lesion load is associated with disability independently from atrophy in MSHugh Kearney, Daniel R Altmann, Rebecca S Samson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 11, 2010
Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosisNikos Gorgoraptis, Claudia A M Wheeler-Kingshott, Thomas M Jenkins, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 2, 2013
Improved MRI quantification of spinal cord atrophy in multiple sclerosisHugh Kearney, Marios C Yiannakas, Khaled Abdel-Aziz, et al.
Neurology|October 10, 2014
HLA-DRB1*15 influences the development of brain tissue damage in early PPMSCarmen Tur, Sreeram Ramagopalan, Daniel R Altmann, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2015
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineJulia Pakpoor, Giulio Disanto, Daniel R Altmann, et al.
Plos One|October 14, 2014
Age related changes in metabolite concentrations in the normal spinal cordKhaled Abdel-Aziz, Bhavana S Solanky, Marios C Yiannakas, et al.
The Lancet. Neurology|July 13, 2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trialRaju Kapoor, Julian Furby, Thomas Hayton, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2010
TI-relaxation time changes over five years in relapsing-remitting multiple sclerosisKonstantinos Papadopoulos, Daniel J Tozer, Leonora Fisniku, et al.
Brain : a Journal of Neurology|December 7, 2007
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomographyAndrew P D Henderson, S Anand Trip, Patricio G Schlottmann, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Neurology|December 18, 2015
White and gray matter damage in primary progressive MS: The chicken or the egg?Benedetta Bodini, Declan Chard, Daniel R Altmann, et al.
Neurology|December 26, 2014
Cervical cord lesion load is associated with disability independently from atrophy in MSHugh Kearney, Daniel R Altmann, Rebecca S Samson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 11, 2010
Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosisNikos Gorgoraptis, Claudia A M Wheeler-Kingshott, Thomas M Jenkins, et al.
Journal of Magnetic Resonance Imaging : JMRI|May 2, 2013
Improved MRI quantification of spinal cord atrophy in multiple sclerosisHugh Kearney, Marios C Yiannakas, Khaled Abdel-Aziz, et al.
Neurology|October 10, 2014
HLA-DRB1*15 influences the development of brain tissue damage in early PPMSCarmen Tur, Sreeram Ramagopalan, Daniel R Altmann, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2015
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineJulia Pakpoor, Giulio Disanto, Daniel R Altmann, et al.
Plos One|October 14, 2014
Age related changes in metabolite concentrations in the normal spinal cordKhaled Abdel-Aziz, Bhavana S Solanky, Marios C Yiannakas, et al.
The Lancet. Neurology|July 13, 2010
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trialRaju Kapoor, Julian Furby, Thomas Hayton, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2010
TI-relaxation time changes over five years in relapsing-remitting multiple sclerosisKonstantinos Papadopoulos, Daniel J Tozer, Leonora Fisniku, et al.
Brain : a Journal of Neurology|December 7, 2007
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomographyAndrew P D Henderson, S Anand Trip, Patricio G Schlottmann, et al.
Pageof 6